Regarding combination therapies, nowadays, the main HCC molecular targets with commercialized drugs are immune targets (PD-1, PD-L1, CTLA-4), VEGF or multi-TK (tyrosine kinases) inhibitors (Figure 5). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.